The CBPO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CBPO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CBPO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CBPO Detailed Price Forecast - CNN Money||View CBPO Detailed Summary - Google Finance|
|View CBPO Detailed Summary - Yahoo! Finance||View CBPO Stock Research & Analysis - Zacks.com|
|View CBPO Trends & Analysis - Trade-Ideas||View CBPO Major Holders - Barrons|
|View CBPO Call Transcripts - NASDAQ||View CBPO Breaking News & Analysis - Seeking Alpha|
|View CBPO Annual Report - CompanySpotlight.com||View CBPO OTC Short Report - OTCShortReport.com|
|View CBPO Fundamentals - TradeKing||View CBPO SEC Filings - Bar Chart|
|View Historical Prices for CBPO - The WSJ||View Performance/Total Return for CBPO - Morningstar|
|View the Analyst Estimates for CBPO - MarketWatch||View the Earnings History for CBPO - CNBC|
|View the CBPO Earnings - StockMarketWatch||View CBPO Buy or Sell Recommendations - MacroAxis|
|View the CBPO Bullish Patterns - American Bulls||View CBPO Short Pain Metrics - ShortPainBot.com|
|View CBPO Stock Mentions - StockTwits||View CBPO Stock Mentions - PennyStockTweets|
|View CBPO Stock Mentions - Twitter||View CBPO Investment Forum News - Investor Hub|
|View CBPO Stock Mentions - Yahoo! Message Board||View CBPO Stock Mentions - Seeking Alpha|
|View Insider Transactions for CBPO - SECform4.com||View Insider Transactions for CBPO - Insider Cow|
|View CBPO Major Holdings Summary - CNBC||View Insider Disclosure for CBPO - OTC Markets|
|View Insider Transactions for CBPO - Yahoo! Finance||View Institutional Holdings for CBPO - NASDAQ|
|View CBPO Stock Insight & Charts - FinViz.com||View CBPO Investment Charts - StockCharts.com|
|View CBPO Stock Overview & Charts - BarChart||View CBPO User Generated Charts - Trading View|
China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant
Posted on Monday June 11, 2018
BEIJING, June 11, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug Administration (the "CFDA") to begin human clinical trials on its Human Fibrin Sealant ("Fibrin Sealant") product. Fibrin Sealant is intended to be used as an adjunct to hemostasis on patients undergoing surgery in case traditional surgical techniques such as sutures, ligatures, and cauteries are ineffective or impractical.
Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Wednesday June 06, 2018
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of China ...
Was China Biologic Products Holdings Inc’s (NASDAQ:CBPO) Earnings Decline Part Of A Broader Industry Downturn?
Posted on Thursday May 31, 2018
Assessing China Biologic Products Holdings Inc’s (NASDAQ:CBPO) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple senseRead More...
Blog Exposure - Portola Pharma Receives Approval from FDA for Its Lead Candidate
Posted on Tuesday May 08, 2018
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Portola Pharma, Inc. (NASDAQ: PTLA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PTLA as the Company's latest news hit the wire. On May 03, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved its lead candidate, Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Active-Investors.com is currently working on the research report for China Biologic Products Holdings, Inc. (NASDAQ: CBPO), which also belongs to the Healthcare sector as the Company Portola Pharma.